As pancreatic cancer awareness month gets underway, scientists at the Cancer Research UK Cambridge Institute are aiming to develop an innovative cancer ‘barcoding’ technology that could unlock the secrets of the disease.

Pancreatic cancer is one of the hardest to treat and advances are desperately needed as only one per cent of patients survive for more than ten years.

Dr Martin Miller and Dr Michael Gill have been awarded a Cancer Research UK Pioneer Award to develop a new ‘barcoding’ technology that could reveal how the disease evades treatment and the immune system.

The pair have been awarded £200,000 from Cancer Research UK to start developing their innovative technology idea – which involves ‘barcoding’ the different cells within a tumour so they can be analysed and tracked in unprecedented detail to see how they interact and evolve.

The Nuclear Tandem Epitope Protein (nTEP) Barcoding technology should enable multiple aspects of a tumour’s environment to be studied simultaneously for the first time.

It will first be tested on pancreatic cancer in mice but could also be used to study other types of the disease.

If we can get a full picture of how those cells interact, assist and obstruct each other then we have a better chance of developing treatments that will work.

Dr Michael Gill, Principle Scientific Associate

Tumours are not just made up of cancerous cells, they are surrounded by a so-called ‘microenvironment’ made up of blood vessels, cells from the immune system and a sticky protein ‘glue’ – known as the matrix – which holds cells together. This microenvironment is much like a community, with elements that work together to assist the cancer cells, hiding them from the immune system, providing them with nutrients and support to help them grow, and helping them resist treatment. Scientists have long studied this microenvironment but have not been able to get the full picture of how those different elements interact, cooperate and evolve.

To fill in these knowledge gaps, Dr Miller and Dr Gill want to develop this new technology that will allow them to track and analyse the different elements of a tumour’s microenvironment in extreme detail.

Dr Martin Miller
Group Leader
Dr Michael Gill
Principle Scientific Associate

 

Dr Martin Miller, Group Leader, said: “We will engineer the cells to produce unique ‘barcodes’, which can then be detected through imaging technology. Much like you would scan a barcode at the till to know what the product is, we’ll be able to identify the different cells simultaneously and understand where they are located and how they interact with each other.

“This will tell us how some of the cells work together, as a community, to help the cancer either resist treatment or to hide from immune system. This knowledge is critical to develop better treatments for people with pancreatic cancer.”

The idea is currently at a very early stage of development. The duo applied for funding from Cancer Research UK’s Pioneer Awards to allow them to develop it further. They were successful, being granted £201,500 over two years.

Dr Michael Gill, Principle Scientific Associate, said: “Being awarded a Pioneer Award is very exciting, we believe in this technology and now have the opportunity to prove that it can work.

“It is often a lengthy and difficult process to get funding for new and innovative ideas at their earliest stage because you might not have the supporting data required. The Pioneer Awards are looking for potential and the panel of experts saw potential in our idea.

“Pancreatic cancer is one of those that is very difficult to treat, we need to better understand it and then we can make advances in treatment. There’s more to cancer than just cancer cells. Solid tumours can be thought of as a rogue organ in the body rather than a growing cluster of cells. If we can get a full picture of how those cells interact, assist and obstruct each other then we have a better chance of developing treatments that will work.”

The Cancer Research UK Pioneer Awards area ‘Dragon’s Den’-like way of funding research. Applications are submitted anonymously, and shortlisted researchers are then given 15 minutes to pitch their ideas to a panel of experts.

Jess Sutcliffe, Senior Research Funding Manager at Cancer Research UK, said: “The Pioneer Awards are as innovative as the research they fund. They allow us to find and fund researchers with big ideas that have the potential to be game-changing for cancer research. The awards back truly novel ideas that have the potential to improve our understanding of cancer, and to find new ways to prevent, diagnose and treat the disease.”

Related links:

Cancer Research UK Pioneer Award
Dr Martin Miller’s Research Group